BBIO at a glance
BridgeBio Pharma, Inc. (BBIO, SEC CIK 1743881) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 31, 2026 and Form 4 insider filings as recently as September 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million (up 126.3% from FY2024) and a net loss of $724.9 million. Diluted EPS was -$3.78.
- As of June 30, 2026, 38 institutional investment managers tracked by SignalX reported holding BridgeBio Pharma, Inc. (BBIO) shares worth $5.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Kumar Neil on September 17, 2026 of 1,279 shares at $69.57 per share.
- In the last 90 days, BBIO insiders reported 0 open-market purchases ($0) and 16 open-market sales ($33.8M) on Form 4, a net sale of $33.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $502.1M
- +126.3% vs prior year
- Insiders · 90 days
- 0 buys · 16 sells
- Net −$33.8M
- 13F holders
- 38 funds
- $5.7B · +1 vs prior quarter
- Latest 8-K
- Aug 31, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical development and commercialization with focus on genetic diseases and novel therapies
- New emphasis on commercialization with FDA approval and US launch of Attruby (net product revenue $362.4M in 2025)
- Strategic shift: Exclusive EU license of acoramidis to Bayer and sale of royalty rights generating $300M upfront cash
- Increased SG&A expenses by $242.3M in 2025 supporting commercial launch of Attruby; R&D expenses decreased $54.5M due to program reprioritization
- Raised $619.3M net from 0.75% convertible notes due 2033 in 2026, used partly for common stock repurchase and refinancing debt
Risk Factors
- Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience
- Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership
- Board of Directors receives periodic updates on cybersecurity risks and risk management from executive leadership
- Data Privacy and Security Committee meets quarterly to discuss cybersecurity risk management and reports to Audit Committee
Management Discussion & Analysis
- No profitability or margin percentages reported
- No cash flow, buybacks, dividends, or capex figures stated
- Forward-looking risks and uncertainties highlighted, no specific guidance or outlook provided
AI summary of the BBIO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $243.7M, up $133.1M YoY from $110.6M, driven by Attruby product revenue $222.4M
- Best-performing line Attruby, product revenue up $150.9M YoY; royalty revenue increased $13.8M to $15.4M
- Operating loss $107.1M vs $134.3M YoY; operating margin 43.9% loss vs 121.4% loss
- Cash, equivalents and securities $720.2M vs $587.5M at December 31, 2025
- Capital deployment included $127.5M share repurchases; $933.9M preferred-stock investment raised
- Outlook: continued operating and net losses expected for at least the next several years; commercialization and development remain key risks
Risk Factors
- Convertible Notes: 2027 and 2031 Notes became convertible July 1–September 30, 2026, potentially reducing liquidity through cash settlement
- Preferred Stock: July 2026 issuance of 933,900 shares convertible into 6,777,704 common shares, creating material dilution risk
- Royalty obligations: Attruby royalty rate may increase from 5% to 10% in 2027, pressuring liquidity and profitability
- Equity financing: May 2026 at-the-market program permits sales of up to $500.0 million, risking dilution and share-price pressure
- Covenant compliance: Royalty arrangements require collateral-backed obligations and operational restrictions, with violations exposing assets to remedies
AI summary of the BBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Voluntary U.S. agreement expands Medicaid access to Attruby through the GENEROUS Model
- Attruby remains available through Medicare Part D without future pricing mandates
Item 8.01: Other Events
- Agreement with U.S. government targets affordability and access for BridgeBio’s future medicines
- Pricing commitment expected to exclude medicines approved exclusively for orphan indications
Item 8.01: Other Events
- BridgeBio launched a securities offering on August 13, 2026
- Offering pricing announced August 14, 2026
Item 1.01: Entry into a Material Definitive Agreement
- KKR Genetic Disorder selling 5,000,000 BridgeBio shares at $78.00 each
- Gross offering value approximately $390 million, accruing to the selling stockholder
Item EX-99.1: Item EX-99.1
- KKR Genetic Disorder L.P. launched a secondary offering of 5,000,000 BBIO shares
- BridgeBio is not selling shares and will receive no proceeds, making this non-dilutive to the company
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Business updates and financial results announced August 10, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $243.7M, including $222.4M Attruby sales versus $110.6M total revenue in Q2 2025
- Attruby momentum supported by treatment-naïve adoption and real-world data showing 37% fewer cardiovascular events versus tafamidis
AI summaries of BBIO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BBIO
Don't miss the next BBIO filing
- Alerts as it files. A push when BBIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BBIO, by share count.
- Ask anything. An AI agent that reads every BBIO filing and answers with sources.
BBIO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kumar Neil | Sell | Sep 17, 2026 | 1,279 | $69.57 |
| Kumar Neil | Sell | Sep 17, 2026 | 8,721 | $69.01 |
| Kumar Neil | Sell | Aug 19, 2026 | 100 | $85.65 |
| Kumar Neil | Sell | Aug 19, 2026 | 1,800 | $84.69 |
| Kumar Neil | Sell | Aug 19, 2026 | 8,100 | $83.86 |
| Kumar Neil | Sell | Aug 18, 2026 | 1,199 | $83.77 |
| Kumar Neil | Sell | Aug 18, 2026 | 17,279 | $82.21 |
| Kumar Neil | Sell | Aug 18, 2026 | 1,900 | $81.15 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $221.9M | $502.1M |
| Operating Income | -$607.4M | -$593.0M | -$523.4M |
| Net Income | -$643.2M | -$535.8M | -$724.9M |
| Op. Margin | - | -267.2% | -104.2% |
| Net Margin | - | -241.4% | -144.4% |
| Balance Sheet | |||
| Total Assets | $546.4M | $919.3M | $936.0M |
| Equity | - | -$1.5B | -$2.1B |
| ROE | - | 36.5% | 34.7% |
| Per Share | |||
| EPS | $-3.95 | $-2.88 | $-3.78 |
| Cash Flow | |||
| Operating CF | - | -$520.7M | -$445.9M |
| CapEx | - | $933K | $1.1M |
Source: XBRL data in BridgeBio Pharma, Inc. (BBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BBIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 38 | $5.74B |
| Q1 2026 | 37 | $6.17B |
| Q4 2025 | 29 | $6.00B |
| Q3 2025 | 31 | $4.07B |
| Q2 2025 | 30 | $3.43B |
| Q1 2025 | 25 | $2.12B |
| Q4 2024 | 20 | $1.51B |
| Q3 2024 | 18 | $1.01B |
- Two Sigma Investments+1.60M (+51%)
- D.E. Shaw & Co+1.09M (+43%)
- JPMorgan Chase & Co+1.09M (+83%)
- Citadel Advisors LLC+586.1K (+18%)
- Renaissance Technologies LLC+491.1K (+134%)
- BlackRock−3.92M (-28%)
- T. Rowe Price Group−2.08M (-55%)
- Viking Global Investors−1.89M (-16%)
- Invesco Ltd−891.9K (-19%)
- State Street Corp−498.4K (-10%)
- Blackstone Group+5.0K
- StoneX Group Inc.+3.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 228 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BBIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 21, 2026 | - | - | - |
| 8-K | Aug 31, 2026 | - | Analysis | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jul 13, 2026 | - | - | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jun 26, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
BBIO SEC filings: frequently asked questions
Are BBIO insiders buying or selling?
In the last 90 days, BridgeBio Pharma, Inc. (BBIO) officers, directors and 10% owners reported no open-market purchases and 16 open-market sales worth $33.8 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BBIO stock?
As of June 30, 2026, the largest BridgeBio Pharma, Inc. (BBIO) holders among the 13F filers tracked by SignalX were BlackRock ($766.2 million), Viking Global Investors ($741.0 million), Vanguard Capital Management LLC ($588.3 million), Vanguard Portfolio Management LLC ($570.3 million), Two Sigma Investments ($351.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BBIO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BridgeBio Pharma, Inc. (BBIO) reported revenue of $502.1 million (up 126.3% from FY2024) and a net loss of $724.9 million. Diluted EPS was -$3.78. The figures come from the XBRL data in the 10-K.
What are the main risks in BBIO's latest 10-K?
In the 10-K filed February 24, 2026, BridgeBio Pharma, Inc. (BBIO) flagged: Cybersecurity risk managed by multidisciplinary Incident Response Team led by Director of Security with 20 years IT experience. Audit Committee oversees enterprise risks, including privacy and cybersecurity, with bi-annual reviews involving legal and executive leadership. (AI summary of the Risk Factors section.)
What did BBIO report in its latest 8-K?
BridgeBio Pharma, Inc. (BBIO) filed an 8-K on August 31, 2026 reporting Item 8.01 (Other Events). Voluntary U.S. agreement expands Medicaid access to Attruby through the GENEROUS Model.
What are the latest BBIO SEC filings?
BridgeBio Pharma, Inc. (BBIO) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 31, 2026 and a Form 4 insider filing on September 21, 2026.
What is BBIO's SEC CIK number?
BridgeBio Pharma, Inc. (BBIO)'s SEC Central Index Key (CIK) is 1743881. EDGAR lists every BBIO filing under that number.
Ask anything about BBIO
The research agent reads BBIO's filings, financials, insider trades and 13F holders, then answers with sources.